SCHEMBL7603166

SCHEMBL7603166

C=CC/N=C/c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA2 P00918 4/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 1/20 0.43
G6PC1 P35575 1/20 0.39
TAAR1 Q96RJ0 2/20 0.39
NOX1 Q9Y5S8 1/20 0.39
GAA P10253 2/20 0.39
CA1 P00915 2/20 0.39
GRIN2D O15399 2/20 0.38
GRIN3B O60391 2/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2A Q12879 2/20 0.38
GRIN2B Q13224 2/20 0.38
GRIN2C Q14957 2/20 0.38
GRIN3A Q8TCU5 2/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8141068 1.00 LMNA (0.48) LMNAL3MBTL1CA2ALDH1A1TSHR
SCHEMBL6888679 1.00 LMNA (0.48) LMNAL3MBTL1CA2ALDH1A1TSHR
SCHEMBL20871102 0.78 RAB9A (0.52) L3MBTL1CA2ALDH1A1SMN1; SMN2RAB9A
SCHEMBL3567649 0.78 NPC1 (0.41) LMNAL3MBTL1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL12493911 0.78 CA2 (0.50) LMNAL3MBTL1CA2ALDH1A1TSHR
SCHEMBL3567647 0.78 NPC1 (0.41) LMNAL3MBTL1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL12493915 0.78 CA2 (0.50) LMNAL3MBTL1CA2ALDH1A1TSHR
SCHEMBL6893957 0.78 ALDH1A1 (0.56) LMNAL3MBTL1ALDH1A1SMN1; SMN2GAA
SCHEMBL7571738 0.77 LMNA (0.48) LMNAL3MBTL1CA2ALDH1A1SMN1; SMN2
SCHEMBL12894229 0.77 CA2 (0.48) LMNAL3MBTL1CA2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60155114-A None JP disclosed
JP-63264411-A None JP disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 US disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 US disclosed
EP-4225447-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 EP disclosed
WO-2023015191-A1 COMPOSITIONS, SYSTEMS AND METHODS FOR ATOM TRANSFER RADICAL ADDITION REACTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-09 WO disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines Universite Paris-Saclay (FR) 2021-06-15 US disclosed
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES Universite Paris-Saclay (FR) 2020-08-13 US disclosed
US-5532360-A REACTING WITH AZOMETHINE COMPOUND TO FORM HETEROCYCLIC COMPOUND NIPPON PAINT CO., LTD. (JP) 1996-07-02 US disclosed
EP-0693474-A1 NOVEL BENZYLAMINOETHOXYBENZENE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF Toyo Boseki Kabushiki Kaisha (JP) 1996-01-24 EP disclosed
EP-0671385-A1 Method for handling (2-alkyl) acryloyl isocyanate, method for producing (2-alkyl)acryloyl isocyanate, heterocyclic compound, and method for producing heterocyclic compound Nippon Paint Co., Ltd. (JP) 1995-09-13 EP disclosed
JP-S63264411-A CARCINOSTATIC AGENT RIKAGAKU KENKYUSHO 1988-11-01 JP disclosed
EP-0111286-B1 NOVEL BETA-LACTAM DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF Sanraku Incorporated (JP) 1988-03-02 EP disclosed
US-4727149-A Preparation of nitriles of fused ring pyridine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1988-02-23 US disclosed
US-4707552-A Preparation of nitriles and thioamides of fused ring pyridine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1987-11-17 US disclosed
JP-S60155114-A CARCINOSTATIC AGENT RIKAGAKU KENKYUSHO 1985-08-15 JP disclosed
US-4517127-A β-Lactam derivatives and process for production thereof SANRAKU-OCEAN CO., LTD. (JP) 1985-05-14 US disclosed
EP-0111286-A1 Novel beta-lactam derivatives and process for production thereof Sanraku Incorporated (JP) 1984-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B LMNA 3702/4885L3MBTL1 3940/4885CA2 2703/4885
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES ADH1C, ADH1A, ADH5 LMNA 944/4885L3MBTL1 4036/4885CA2 4835/4885
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines ADH1C, PNMT, ADH1A LMNA 1096/4885L3MBTL1 3863/4885CA2 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.